X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
hiv infections - drug therapy (9) 9
performing operations (8) 8
transporting (8) 8
blasting (7) 7
female (7) 7
heating (7) 7
lighting (7) 7
mechanical engineering (7) 7
weapons (7) 7
male (6) 6
adult (5) 5
electricity (5) 5
index medicus (5) 5
physics (5) 5
aged (4) 4
anti-hiv agents - therapeutic use (4) 4
antiretroviral therapy (4) 4
cycles (4) 4
details of fluid-pressure systems, not otherwise provided for (4) 4
fluid-pressure actuators (4) 4
fluid-pressure actuators, e.g. servo-motors (4) 4
hiv (4) 4
hiv-1 (4) 4
hydraulics or pneumatics in general (4) 4
infectious diseases (4) 4
land vehicles for travelling otherwise than on rails (4) 4
middle aged (4) 4
polymorphism, genetic (4) 4
powered propulsion of sledges or (4) 4
rider propulsion of wheeled vehicles or sledges (4) 4
systems acting by means of fluids in general (4) 4
transmissions specially adapted for such vehicles (4) 4
anti-hiv agents - administration & dosage (3) 3
basic electric elements (3) 3
bottles, jars or similar containers (3) 3
capacitors (3) 3
capacitors, rectifiers, detectors, switching devices orlight-sensitive devices, of the electrolytic type (3) 3
cytochrome p450 (3) 3
dispensing, delivering or transferring liquids, not otherwiseprovided for (3) 3
efavirenz (3) 3
engineering elements and units (3) 3
gene frequency (3) 3
general measures for producing and maintaining effectivefunctioning of machines or installations (3) 3
general tagging of cross-sectional technologies spanning over several sections of the ipc (3) 3
general tagging of new technological developments (3) 3
hematology, oncology and palliative medicine (3) 3
hiv infections - complications (3) 3
hiv infections - genetics (3) 3
liquid handling (3) 3
lubricating (3) 3
medicine & public health (3) 3
opening, closing (3) 3
pharmacology & pharmacy (3) 3
safety (3) 3
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (3) 3
therapeutic drug monitoring (3) 3
thermal insulation in general (3) 3
adenine - administration & dosage (2) 2
adenine - adverse effects (2) 2
adenine - analogs & derivatives (2) 2
adolescent (2) 2
alleles (2) 2
anti-hiv agents - adverse effects (2) 2
anti-hiv agents - blood (2) 2
antiretroviral therapy, highly active (2) 2
aryl hydrocarbon hydroxylases - genetics (2) 2
building (2) 2
case report (2) 2
ceilings (2) 2
complications and side effects (2) 2
cyclohexanes - therapeutic use (2) 2
cytochrome p-450 cyp2b6 (2) 2
drug monitoring (2) 2
drug therapy (2) 2
efficacy (2) 2
fixed constructions (2) 2
floors (2) 2
general building constructions (2) 2
genetic aspects (2) 2
genetic polymorphism (2) 2
glucuronosyltransferase - genetics (2) 2
heterozygotes (2) 2
hiv infection (2) 2
hiv infections - blood (2) 2
hiv-infected patients (2) 2
human immunodeficiency virus--hiv (2) 2
human immunodeficiency virus-1 infection (2) 2
insulation or other protection of buildings (2) 2
japan (2) 2
measuring (2) 2
organophosphonates - administration & dosage (2) 2
organophosphonates - adverse effects (2) 2
oxidoreductases, n-demethylating - genetics (2) 2
patients (2) 2
plasma concentration (2) 2
polymer (2) 2
population (2) 2
pyridazines - therapeutic use (2) 2
raltegravir (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 09/2017, Volume 17, Issue 1, pp. 622 - 8
Background: Dolutegravir (DTG) is metabolized mainly by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1), and partly by cytochrome P450 3A... 
UGT1A1 gene polymorphism | Plasma trough concentration | Neuropsychiatric adverse events | Dolutegravir | POPULATION | INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | EFFICACY | HIV-1-INFECTED PATIENTS | INTOLERANCE | DISCONTINUATION | NAIVE PATIENTS | PHARMACOKINETICS | Neuropsychiatric adverseevents | COMBINATION ANTIRETROVIRAL THERAPY | HIV-1 - pathogenicity | Dizziness - genetics | Gene Frequency | HIV Infections - genetics | Humans | Middle Aged | Asian Continental Ancestry Group - genetics | Dizziness - chemically induced | Male | Polymorphism, Genetic | Sleep Initiation and Maintenance Disorders - chemically induced | Glucuronosyltransferase - genetics | Anxiety - genetics | HIV Integrase Inhibitors - adverse effects | Heterocyclic Compounds, 3-Ring - blood | Heterocyclic Compounds, 3-Ring - adverse effects | Alleles | Sleep Initiation and Maintenance Disorders - genetics | Adult | Female | HIV Infections - drug therapy | HIV Integrase Inhibitors - blood | Anxiety - chemically induced | Infection | Complications and side effects | Analysis | Genetic aspects | HIV (Viruses) | Health aspects | Genetic polymorphisms | Risk factors | Cytochrome | Headache | Statistical analysis | Cytochrome P450 | Heterozygotes | Clinical trials | Viruses | Multivariate analysis | Gene polymorphism | Patients | Homozygotes | Sleep disorders | Acquired immune deficiency syndrome--AIDS | Insomnia | Human immunodeficiency virus--HIV | Uridine | Anxiety | Drug therapy | Polymorphism | Glucuronosyltransferase
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 07/2004, Volume 319, Issue 4, pp. 1322 - 1326
Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver. We analyzed the genotypes of CYP2B6 and their contribution to plasma EFV... 
HIV-1 | Cytochrome P450 | Genetic polymorphism | Plasma concentration | Efavirenz
Journal Article
Internal Medicine, ISSN 0918-2918, 2016, Volume 55, Issue 20, pp. 3059 - 3063
An elderly woman with human immunodeficiency virus-1 infection developed short bowel syndrome as a result of extensive intestinal resection. Considering the... 
human immunodeficiency virus-1 infection | antiretroviral therapy | short bowel syndrome | therapeutic drug monitoring | Therapeutic drug monitoring | Short bowel syndrome | Antiretroviral therapy | Human immunodeficiency virus-1 infection | MEDICINE, GENERAL & INTERNAL | PLASMA | PROTEASE INHIBITORS | P-GLYCOPROTEIN
Journal Article
The Journal of Medical Investigation, ISSN 1343-1420, 2013, Volume 60, Issue 1.2, pp. 35 - 40
Rilpivirine (TMC-278) is a second-generation non-nucleoside reverse transcriptase inhibitor that is high potent against both wild-type and drug-resistant HIV-1... 
LC-MS | HIV | therapeutic drug monitoring | rilpivirine | Therapeutic drug monitoring | Rilpivirine
Journal Article
Journal of Infection and Chemotherapy, ISSN 1341-321X, 2012, Volume 18, Issue 2, pp. 169 - 174
Journal Article
Journal of Infection and Chemotherapy, ISSN 1341-321X, 2012, Volume 18, Issue 5, pp. 675 - 682
Journal Article
Gastroenterological Endoscopy, ISSN 0387-1207, 2016, Volume 58, Issue 5, pp. 1044 - 1049
Journal Article
The journal of medical investigation : JMI, 2013, Volume 60, Issue 1-2, p. 35
Rilpivirine (TMC-278) is a second-generation non-nucleoside reverse transcriptase inhibitor that is high potent against both wild-type and drug-resistant HIV-1... 
Reverse Transcriptase Inhibitors - blood | HIV-1 - drug effects | Pyrimidines - blood | Rilpivirine | Humans | Nitriles - blood | Anti-HIV Agents - blood | Chromatography, Liquid - methods | Mass Spectrometry - methods
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 10/2016, Volume 19, Issue 8(Suppl 7), pp. 21487 - n/a
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 11/2007, Volume 45, Issue 9, p. 1230
  Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G[arrow right]T... 
Proteins | Genotype & phenotype | Side effects | Inhibitor drugs | Human immunodeficiency virus--HIV | Nervous system | Drug dosages
Journal Article
Journal Article
IRYO - Japanese Journal of National Medical Services, ISSN 0021-1699, 02/2004, Volume 58, Issue 2, pp. 99 - 101
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.